The 4 mg tablet and the capsule are different prescriptions

Write tablet or capsule on the Zanaflex script

Food hits the capsule harder than the scored 4 mg tablet. A silent form swap changes exposure. Coupon tools often quote 2 mg tablets × 30. This bench lists those bands. It does not fill muscle relaxants.

Ciprofloxacin plus tizanidine is a stop, not a tweak

CYP1A2 inhibitors - ciprofloxacin, fluvoxamine - are contraindications. Syncope admissions come from that pair. Screen every new antibiotic against the tizanidine line before the first dose.

2 mg tablet coupon bands August 2026

Costco, Kroger, Publix, Target - tablet rows only in the quotes below. August 2026 snapshots. ZIP moves the dollar. Script required.

Spasticity Relief That Starts With the Dosage Form

The tizanidine admission I remember: MS patient, stable for years, urgent care cipro for UTI, found on the bathroom floor next morning. CYP1A2 inhibition is not a footnote — it is the reason you screen every new prescription.

Spasticity after MS or spinal cord injury hurts, wrecks sleep, and makes catheterization miserable. Tizanidine dampens polysynaptic reflex hyperactivity centrally — not a peripheral paralytic, not a train-of-four drug.

Low back spasm in neurologically intact adults is off-label with thin evidence. When tizanidine shows up on any med list, the PK traps still apply.

Rehab teams care about dressing, transfers, and sleep hours — not Ashworth scores in isolation. Nighttime dosing alone often wins when spasms cluster overnight.

Insurance swaps capsule for tablet without notifying the prescriber. Document dosage form next to milligram dose in the problem list or you will retitrate in the ER.

Whoever refills tizanidine owns CYP1A2 screening — new SSRIs and antibiotics are the usual ambush.

Stroke spasticity gets tizanidine off-label all the time. Orthostatic hypotension in elderly patients on three antihypertensives is the price — start low, measure standing BP, accept partial tone reduction.

Discharge from rehab with 'tizanidine 4 mg TID' without goal is how daytime sedation returns. Ask what function the dose protects.

Central Alpha-2 Tone, Not a GABA Pill

Label check: tizanidine is an imidazoline derivative and alpha-2 adrenergic agonist in spinal cord interneurons. Presynaptic alpha-2 activation reduces glutamate and aspartate release, dampening polysynaptic excitation of alpha motor neurons.

Ashworth scale improvement and reduced spasm frequency follow without flaccid paralysis typical of neuromuscular blockers. Voluntary strength at low doses is often preserved better than many patients expect from a 'muscle relaxant' label.

Supraspinal alpha-2 effects produce sedation, dry mouth, and hypotension — clonidine-family physiology. Dose titration usually stops at tolerability before maximal antispastic effect.

No GABA-A potentiation unlike baclofen. Combining tizanidine with baclofen, benzodiazepines, gabapentinoids, or opioids stacks sedation and fall risk — common in SCI and MS polypharmacy.

Botulinum toxin for focal spasticity; tizanidine for more generalized tone. They stack in real rehab programs — not either-or.

Dantrolene acts peripherally on sarcoplasmic reticulum — different mechanism, hepatotoxicity profile, and exam contrast point.

Label check: compared with baclofen, tizanidine trades less weakness for more hypotension — patient preference after trial matters more than my habit.

Clonidine and tizanidine share alpha-2 physiology; I think of hypotension and dry mouth as class effects, not surprises.

Label check: spasticity flares with infection, constipation, and skin breakdown — treat triggers before reflexively doubling tizanidine.

I document 'capsule fasting' or 'capsule with dinner' in the chart — future me and covering colleagues need the same instruction.

Tablet Versus Capsule Fed-State Split

Oral bioavailability averages near 40% with wide inter-patient spread. Peak plasma concentration occurs about one hour fasting; half-life is short — roughly 2.5 hours — so clinical effect tracks peaks more than troughs.

CYP1A2 is the dominant clearance route. Fluvoxamine can raise tizanidine AUC more than ten-fold in interaction studies — contraindicated, not a dose-adjustment problem. Ciprofloxacin is the quinolone you see on real charts with the same contraindication.

Label check: smokers induce CYP1A2 and may need higher doses; smoking cessation can raise levels unexpectedly. Oral contraceptives may inhibit CYP1A2 modestly.

Label check: capsule versus tablet: FDA bridging studies showed capsules taken with food can approximately double Cmax versus fasting; tablets show a different food effect magnitude. Capsules and tablets are not bioequivalent mg-for-mg — retitrate from 2 mg when switching forms after generic substitution.

Protein binding ~30%. Renal elimination of metabolites matters in severe renal failure; hepatic clearance remains primary.

Label check: short half-life supports TID scheduling when daytime coverage is needed; bedtime-only regimens work for nocturnal spasms.

I draw a line on the bottle label: fasting capsule versus with-food capsule — patients forget verbal instructions by first refill.

CYP1A2 inducers like rifampin can make tizanidine feel 'worn off' mid-day — smoking cessation does the opposite; life changes are dose changes.

Oral contraceptives mildly inhibit CYP1A2 — usually not dramatic alone, but stacked with cimetidine or fluvoxamine becomes dangerous.

Peak effect about one hour — useful for scheduling before PT; also means hypotension peak when standing too soon after dose.

Renal impairment slows metabolite clearance — parent drug half-life still short but exposure may accumulate in severe CKD; label lower max doses.

Tone Scores That Still Need a CYP1A2 Screen

MS registration trials over four to eight weeks showed improved Ashworth scores and patient global impression at total daily doses of 8–12 mg divided versus placebo. Effect sizes are modest — symptomatic, not disease-modifying.

Onset within one to two hours supports dosing before therapy or at bedtime for nocturnal spasms. If spasms cluster at night, maximize evening dose before pushing daytime doses that impair alertness.

Crossover comparisons with baclofen show similar group-level antispastic efficacy; individual tolerance differs — weakness with baclofen, hypotension with tizanidine.

SCI populations show reduced tone and improved comfort; functional gains (transfers, catheterization) matter more than scale points.

Rebound hypertension and tachycardia can follow abrupt discontinuation after chronic high-dose use — clonidine-like withdrawal. Taper over days to weeks when stopping after prolonged therapy.

Stroke spasticity uses tizanidine off-label frequently; monitor hypotension in older patients on antihypertensives.

Trial effect sizes are modest — I tell patients we are aiming for sleep and hygiene, not normal tone. Expecting Ashworth zero sets everyone up for frustration.

Label check: rebound hypertension after abrupt stop is clonidine-like — write taper instructions on the bottle when stopping after months above 8 mg daily.

Functional goal interview belongs in the chart: 'sleeps through night' versus 'needs daytime arm tone for feeding' — two different regimens.

Crossover trials show group equivalence with baclofen; individual patients pick weakness versus hypotension — honor that after two-week trial.

Placebo response in spasticity scales is small but non-zero — do not chase Ashworth points if function already improved.

Dosing and Titration

Start 2 mg at bedtime. Increase 2–4 mg per day every 3–7 days by effect and blood pressure. Max 36 mg/day divided — many stop at 8–16 mg because sedation wins.

MS/SCI maintenance often 8–24 mg/day — TID or larger bedtime fraction for nocturnal spasms.

Hepatic impairment: lower doses; severe liver disease raises exposure — specialist oversight.

Capsule-to-tablet or reverse: restart at 2 mg bedtime per FDA. Milligram-for-milligram assumption causes harm.

Missed dose: take next scheduled; do not double. Short half-life means hypotension stacks within hours if you double.

Not PRN for acute back spasm — chronic spasticity titration applies even off-label.

Before PT: dose 1–2 hours prior if daytime coverage needed; skip morning dose if goal is sleep only.

Maximum 36 mg/day on label — patients rarely tolerate near max because hypotension arrives first; do not treat label max as target.

Split bedtime dose versus single 8 mg — some patients prefer 4 mg at 9 p.m. and 4 mg at midnight for spasms after turns.

Cipro and Fluvoxamine Are Stops, Not Tweaks

Contraindicated with fluvoxamine and ciprofloxacin — CYP1A2 inhibition. Other quinolones vary; avoid when alternatives exist if tizanidine must continue.

CYP1A2 inhibitors: cimetidine, oral contraceptives, vemurafenib — monitor blood pressure and sedation.

CYP1A2 inducers: rifampin, phenytoin, carbamazepine — may reduce tizanidine effect.

Additive CNS depression with opioids, benzodiazepines, baclofen, gabapentin, alcohol — fall risk in wheelchair users and ambulatory MS patients.

Antihypertensives plus tizanidine: orthostatic hypotension and syncope — common inpatient reconciliation issue.

Levofloxacin and moxifloxacin have weaker but not zero CYP1A2 effect — prefer non-quinolone antibiotics for UTIs when tizanidine is essential.

Modafinil does not replace sleep hygiene in MS fatigue, but it coexists on many med lists with tizanidine — watch stacked wake-sleep pharmacology in counseling.

Label check: zolpidem plus tizanidine plus baclofen at bedtime in SCI — I pick one sedating agent to own the night, not three at full dose.

Melatonin OTC plus tizanidine — patient does not list it; ask about supplements during med rec.

Grapefruit and tizanidine — not the classic CYP3A4 story, but erratic diet still shifts capsule exposure; consistency matters.

Hypotension, Dry Mouth, and Rebound Tone

Sedation, dry mouth, dizziness, and hypotension dominate — often dose-limiting before maximal antispastic benefit.

Hepatic transaminase elevations — monitor LFTs per label when dose increases or with hepatic comorbidity.

Hallucinations and psychosis are rare at standard doses; report in renal/hepatic impairment and drug interaction scenarios.

Bradycardia reported — watch with beta-blocker co-therapy.

Withdrawal hypertension if stopped abruptly after high chronic doses — taper.

No controlled substance schedule federally, but sedation impairs driving — counsel accordingly.

Dry mouth leads to dental caries in long-term users — mention oral hygiene; not a reason to stop if spasticity controlled.

Vivid dreams reported anecdotally — distinguish from psychosis; dose timing shift to earlier evening sometimes helps.

Concurrent clonidine for hypertension plus tizanidine — hypotension multiplier; pick one alpha-2 strategy when possible.

Hepatic Impairment and the Elderly Titration

Elderly stroke survivors: start 2 mg bedtime only; orthostatic vitals before titration.

Renal impairment: reduce dose or extend interval in severe CKD.

Pediatric spasticity: off-label; weight-based protocols in specialty centers.

Pregnancy: limited data; use lowest effective dose if spasticity threatens function or skin integrity.

Lactation: unknown exposure — balance against maternal need.

Label check: wheelchair users: reduce adductor tone for transfers while preserving stability — goal-directed PT dosing beats automatic TID on discharge.

Pediatric spasticity off-label: weight-based protocols in specialty centers — adult mg/day tables do not translate.

Pregnancy spasticity: lowest dose that protects skin and function — data sparse, function matters.

Label check: elderly nursing home stroke patient on tizanidine plus trazodone plus quetiapine — fall with subdural; sedative stack review before raising tizanidine.

Lactation: unknown exposure — if spasticity threatens care, discuss pump-and-discard options with patient rather than silent stop without plan.

LFTs and Blood Pressure After Each Step

Sitting and standing BP after every dose increase during titration — syncope in wheelchair users is not minor.

Med rec every visit: new antibiotics, antidepressants, sleep aids.

Capsule vs tablet on the prescription and patient handout — pharmacy switches silently.

No driving until they know their sedation response; MS patients often still drive — individual call.

Taper plan on discharge if above 8 mg daily for months.

Interaction with fluoroquinolones is pharmacokinetic, not allergy — do not rely on allergy list alone.

Heavy breakfast with capsules? Fine — if every day. Random meals mean random sedation.

Family asks to hold tizanidine before MRI — sedation risk with contrast premedication stacks; coordinate with radiology same day.

Home health nurse reports 'BP low' after tizanidine increase — confirm orthostatic technique; sitting-only vitals miss the problem.

Label check: patient crushes tablet for dysphagia — bioavailability changes; use liquid compounding or alternate route discussion with pharmacy.

Fall with hip fracture on tizanidine — med rec at admission must flag CYP1A2 before new antibiotics started inpatient.

Outpatient infusion center sees MS patient on tizanidine — verify UTI antibiotic choice if treating same day.

Inpatient and Rehab Practice

MAR must say capsule or tablet — pharmacy clarification on admission beats sedation or loss of effect on day two.

UTI in MS on tizanidine: nitrofurantoin or fosfomycin, not cipro. I have seen this missed on night float.

Label check: fluvoxamine for OCD plus tizanidine: switch SSRI to sertraline or escitalopram; hold tizanidine until the SSRI change clears.

Night-only 4–8 mg controls nocturnal spasms without daytime fog — ask before default TID on discharge.

Intrathecal baclofen plus low oral tizanidine for breakthrough — coordinate with rehab; hypotension stacks fast.

Ashworth one-point improvement that eases catheterization in SCI beats a three-point change the patient cannot feel.

Generic capsule-to-tablet switch is the top cause of 'tizanidine stopped working' — retitrate from 2 mg, do not blame the patient.

Abrupt stop after 24 mg daily: withdrawal hypertension. Taper 2 mg every few days.

EMR hard-stop on quinolone plus tizanidine saves syncope admissions — turn it on if your system allows.

Admission med list from outside hospital lists 'muscle relaxer' — clarify tizanidine dose, form, and timing before first inpatient dose.

Rehab gym session at 9 a.m. with 8 a.m. tizanidine and 8 a.m. baclofen — expect orthostatics; schedule one sedating agent later if gait training is priority.

Discharge to subacute rehab without MAR form specification — fax explicit capsule/tablet instruction to receiving facility.

Psychiatry consult for depression in MS — SSRIs screened for CYP1A2 before tizanidine adjustment assumed unnecessary.

Long-term care resident on tizanidine for stroke spasticity — standing BP before bath transfers; falls cluster during ADLs.

Patient requests 'stronger muscle relaxer' — explain alpha-2 mechanism and hypotension ceiling; baclofen trial may fit better.

Summer camp nurse calls — MS camper on tizanidine, new antibiotic for cellulitis; read antibiotic name aloud before approving fax order.

Video visit spasticity follow-up — ask patient to show pill bottle form factor on camera; catches capsule-tablet switch.

Adaptive driving evaluation for MS — tizanidine timing relative to drive time should be documented for evaluator.

Aquatic therapy plus tizanidine — pool BP changes and alpha-2 hypotension stack; first session observe standing exit.

Tizanidine held for procedure NPO — spasticity rebound during hospitalization; restart low when eating resumes.

EMR problem list 'spasticity' without drug form — add 'tizanidine capsule 4 mg qHS' not generic 'Zanaflex.'

Night float covers MS service — sign-out must include 'on tizanidine — no quinolones' not just drug name.

Tizanidine is inexpensive and effective for the right patient — underused in nocturnal spasticity, overused as PRN back spasm, dangerous with cipro.

Every orthostatic syncope workup on tizanidine should include new meds in last thirty days — antibiotics and SSRIs first.

Capsule taken with heavy breakfast doubles peak — patients blame MS progression when the real issue is pharmacy form plus meal timing.

Label check: smoking status belongs in tizanidine follow-up — CYP1A2 induction from tobacco is a dose variable, not a lifestyle footnote.

Label check: discharge TID tizanidine without functional indication — push back; night-only dosing helps many SCI patients stay alert for work.

Fluvoxamine and cipro are never 'monitor closely' with tizanidine — they are stop.

Document capsule versus tablet on every refill request — pharmacy switches are silent.

Rehab Double-Orders That Drop Blood Pressure

MS clinic, stable 4 mg capsule TID fasting for two years. Insurance fills tablet; patient takes with breakfast. Sedated by 10 a.m., thinks disease progressed. Retitrate from 2 mg bedtime, pick fed or fasted and stay consistent.

Label check: sCI patient on tizanidine 6 mg bedtime, tamsulosin, amlodipine — orthostatic syncope in transfer training. Drop or reduce one hypotensive agent before chasing neuro workup.

Psychiatry starts fluvoxamine; orthopedics continues tizanidine for spasticity — nobody runs interaction check. Hold tizanidine, change SSRI, document why.

Smoker on 8 mg TID quits tobacco; sedation returns at same dose. CYP1A2 induction reversed — cut dose.

Stroke rehab, age 78, tizanidine 2 mg bedtime — orthostatic BP 110/70 to 85/55 standing. Stop titration; spasticity may be less dangerous than hip fracture.

Label check: inpatient PT notes 'patient too sedated for gait' at 10 a.m. — MAR shows capsule given with breakfast starting this week. Timing and form, not disease progression.

Caregiver asks for PRN tizanidine for spasms — explain scheduled dosing and short half-life; PRN leads to stacking hypotension.

MS patient drives to clinic — tizanidine 4 mg morning dose; counsel that sedation varies by day and food; document conversation.

Rehab discharge summary lists baclofen and tizanidine at full dose without indication for both — call prescriber before filling both at maximum.

Hepatic transaminase bump on tizanidine — hold, recheck, restart lower; do not automatically blame statin without reviewing whole med list.

Night nurse gives tizanidine capsule with midnight snack when patient was fasting two weeks — new spasms and new sedation same shift.

What Rehab Misses on Zanaflex Forms

MS patient, new cipro from urgent care — contraindicated; call pharmacy, switch antibiotic today.

Capsule 4 mg TID with breakfast doubles peak — sedated mid-morning. Pick fasting or consistent fed, not random.

Tablet after insurance change 'not working' — retitrate from 2 mg; generic is not broken, PK changed.

Tizanidine plus tamsulosin plus amlodipine — orthostatic fall. Reduce one drug, not reflex fludrocortisone.

Night spasm SCI: 6 mg bedtime only, 0 mg daytime — function met, leave it alone.

Baclofen 20 mg TID plus tizanidine 4 mg bedtime — rehab planned it; don't duplicate without asking.

Fluvoxamine plus tizanidine — hold tizanidine, change SSRI same week.

Smoker quits, same dose, new sedation — cut tizanidine.

Ashworth 0 but patient sleeps through the night — that's success.

Stroke spasticity 2 mg bedtime elderly — orthostatics before each bump.

Not PRN for acute back spasm — titration protocol still applies.

EMR hard-stop cipro-tizanidine — worth the alert fatigue battle.

Spasticity worse in UTI — treat infection before doubling tizanidine; fever and dehydration lower seizure threshold and worsen tone.

Heat exposure worsens MS symptoms — patient links tizanidine failure in summer; hydration and cooling before dose escalation.

Cannabis for spasticity plus prescribed tizanidine — additive sedation; ask openly, adjust doses.

Intrathecal baclofen pump alarm with oral tizanidine at home — neurosurgery and rehab must co-own hypotension plan.

Workplace drug test — tizanidine not opiate; patients confuse muscle relaxer with controlled substance anxiety.

Holiday alcohol with unchanged tizanidine dose — orthostatic syncope at family gathering; seasonal counsel matters.

Pediatric CP spasticity off-label — weight-based in specialty clinic only; adult tablet splitting in kitchen is error-prone.

Tizanidine withdrawal after long high-dose use mimics clonidine rebound — warn patients stopping for side effects to taper, not stop suddenly.

Functional spasticity management beats dose chasing — if transfers improved at 4 mg bedtime, 12 mg TID may only add sedation.

Cipro is the landmine; nitrofurantoin is the path — memorize that pair for every tizanidine patient with UTI.

Ashworth zero with good sleep is a win — do not keep titrating because the scale says there is still tone.

Write the Dosage Form or the Script Fails

Confirm MS or SCI spasticity — not isolated low back spasm without neurologic disease.

CYP1A2 screen on every med rec: fluvoxamine and cipro contraindicated; levofloxacin caution; nitrofurantoin for UTI when tizanidine must continue.

Write capsule or tablet on the script and problem list.

Start 2 mg bedtime; increase 2–4 mg every 3–7 days by effect and blood pressure. Max 36 mg/day — many stop lower.

Functional goal first: nocturnal spasms only may need bedtime dose alone.

Orthostatic vitals after each titration step.

Review baclofen, benzos, opioids, gabapentin before pushing tizanidine higher.

Discharge: scheduled dosing, not PRN muscle relaxer; taper plan if stopping after months above 8 mg daily.

Capsule-Tablet PK Tables on the PI

FDA 1996 for spasticity in MS and SCI — central alpha-2 agonist, not neuromuscular blocker.

CYP1A2 clearance; fluvoxamine and ciprofloxacin contraindicated per label interaction data.

Capsule-tablet non-interchangeability: food effect on capsules can ~double Cmax — retitrate on form switch.

Half-life ~2.5 hours; TID when daytime coverage needed, bedtime-only often enough for nocturnal spasms.

Withdrawal hypertension after abrupt stop from chronic high doses — taper like clonidine.

Modest Ashworth improvements in trials; functional endpoints drive real prescribing.

Ward and Rehab Notes

Label check: baclofen versus tizanidine: weakness versus hypotension — patient preference after one-week trial tells you more than guidelines.

SCI C6 tetraplegia: night tizanidine for spasms during catheterization and dressing — functional endpoints on discharge checklist.

Pharmacy should notify prescriber on capsule-tablet substitution — if your system does not, write 'do not substitute form' or accept retitration calls.

PT timing: dose one to two hours before session if daytime coverage needed; avoid peak sedation overlapping gait training.

Dantrolene hepatotoxicity contrast — different class, different monitoring, good board-exam separator.

Cyclobenzaprine in elderly back spasm: anticholinergic burden versus tizanidine hypotension — neither is free lunch off-label.

Duplicate tizanidine orders on MAR from admission plus rehab consult — reconciliation prevents double hypotension.

Label check: spasticity clinic compares baclofen pump refill timing with oral tizanidine trough sedation — coordinate same-day phone visit when pump dose changes.

Urgent care prescribes cyclobenzaprine for back pain; patient also on tizanidine for MS — duplicate muscle relaxant classes, different mechanisms, same fall risk.

Smoking cessation class enrollment — flag tizanidine dose review at four weeks smoke-free.

Telehealth refill of tizanidine without blood pressure check in six months — orthostatic symptoms may have crept in unnoticed.

SCI annual exam: spasms improved but blood pressure 85/50 sitting — tizanidine dose may need reduction even when spasticity controlled.

Occupational therapy hand splinting plus tizanidine — tone management is multimodal; oral drug is not sole plan.

Prior authorization for brand Zanaflex — if generic switch occurs, send one-page retitration instructions with approval.

Label check: wheelchair pressure injury from adductor spasm — tizanidine may loosen tone enough for positioning; still need wound care.

MS relapse on steroids plus home tizanidine — steroid fluid retention and tizanidine hypotension; recheck BP during relapse.

Care partner administers evening meds — teach form and food rules; errors cluster when caregiver changes.

Form on the Rx, Then Screen CYP1A2

Label check: tizanidine reduces spasticity via spinal alpha-2 agonism in MS and SCI. Sedation and hypotension usually limit dose before spasticity fully yields.

Label check: fluvoxamine and ciprofloxacin are contraindicated — not 'monitor.' Capsules and tablets differ with food; retitrate when pharmacy changes form.

Label check: nighttime dosing alone often enough. Screen every new drug for CYP1A2. Falls and syncope are preventable if you treat dosage form and interactions as seriously as the spasticity itself.

Rehab success is functional — sleep, catheterization, transfers — not Ashworth perfection on a discharge summary.

If tizanidine is on the list, CYP1A2 and dosage form are on the list. Every refill. Every new antibiotic.